Arcus Biosciences, Inc.
RCUS
$9.34
-$0.20-2.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.00M | 48.00M | 39.00M | 145.00M | 31.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.00M | 48.00M | 39.00M | 145.00M | 31.00M |
| Cost of Revenue | 101.00M | 123.00M | 10.00M | 109.00M | 93.00M |
| Gross Profit | -75.00M | -75.00M | 29.00M | 36.00M | -62.00M |
| SG&A Expenses | 28.00M | 30.00M | 30.00M | 32.00M | 29.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.00M | 153.00M | 145.00M | 141.00M | 122.00M |
| Operating Income | -103.00M | -105.00M | -106.00M | 4.00M | -91.00M |
| Income Before Tax | -93.00M | -92.00M | -93.00M | -4.00M | -80.00M |
| Income Tax Expenses | 1.00M | -- | -- | -- | 1.00M |
| Earnings from Continuing Operations | -94.00M | -92.00M | -93.00M | -4.00M | -81.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.00M | -92.00M | -93.00M | -4.00M | -81.00M |
| EBIT | -103.00M | -105.00M | -106.00M | 4.00M | -91.00M |
| EBITDA | -100.00M | -103.00M | -104.00M | 7.00M | -88.00M |
| EPS Basic | -1.03 | -1.01 | -1.02 | -0.05 | -1.08 |
| Normalized Basic EPS | -0.63 | -0.63 | -0.64 | 0.12 | -0.67 |
| EPS Diluted | -1.03 | -1.01 | -1.02 | -0.05 | -1.08 |
| Normalized Diluted EPS | -0.63 | -0.63 | -0.64 | 0.12 | -0.67 |
| Average Basic Shares Outstanding | 91.70M | 91.40M | 91.10M | 86.20M | 75.00M |
| Average Diluted Shares Outstanding | 91.70M | 91.40M | 91.10M | 86.20M | 75.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
